• Tue news: Pfizer explores sale of hospital drugs unit. FDA declines full approval of Ocaliva. AZ better than expected Q3 results. Pfizer, Lilly telehealth platforms draw scrutiny. 23andMe cutting lays off 40%. See more on our front page

Another PhIII RSV failure thumps beleaguered Novavax, but execs claim there's a way...

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Feb 28, 2019 at 10:22: AM
via Back in November 2016, when Novavax was picking up the scraps from a Phase III crash of its RSV vaccine in older adults, the company pointed to the Gates Foundation-backed program to test the vaccine in infants as a “significant commercial opportunity.” It went on to become the lead program as Novavax mounted an arduous comeback campaign for RSV-F vaccine.

article source
 




Top Bottom
Back
Quote